NR4A1 and aneurysmal bone cyst: ,4,5 In the PALOMA-2 and PALOMA-3 trials, patient-reported QoL was an integral component of the benefit-risk assessment of palbociclib treatment in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) ABC/mBC.6